Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?

Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response.MethodsWe included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2004
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/27041
Acceso en línea:
https://doi.org/10.1016/j.semarthrit.2003.11.002
https://repository.urosario.edu.co/handle/10336/27041
Palabra clave:
Systemic lupus erythematosus
Cytokines
TNF-?
IL-10IL12
Autoantibodies
SLEDAI
Rights
License
Restringido (Acceso a grupos específicos)
id EDOCUR2_214a4493d3c38b04ddf3e9bb92289fd3
oai_identifier_str oai:repository.urosario.edu.co:10336/27041
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 580969d2-cc6b-4ffe-a1d8-9a3beec278cfdb6634cb-78db-456d-82d5-fa7140510037c5e15d68-2e79-46cc-994c-608ea4c1dc2311dd66da-4e02-4f6f-9171-5c31eb777d1b47d226c1-f36d-43c4-a449-590b2286830c194747786002020-08-19T14:40:50Z2020-08-19T14:40:50Z2004-06Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response.MethodsWe included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor (TNF) ?, interferon (IFN) ?, interleukin (IL)-12p70, IL-10, and IL-4, as well as anti-DNA, -Ro, -La, -RNP, and -Sm antibodies were determined by enzyme-linked immunosorbent assay. Disease activity was recorded according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and classified as very active (SLEDAI ? 13), moderately active (SLEDAI: 3–12), or inactive (SLEDAI ? 2).ResultsThe mean age of the patients was 34.2 ± 12.6 years, and the mean duration of disease was 4.9 ± 7.6 years. Twelve patients (23%), 20 patients (34.5%), and 20 patients (34.5%) had highly, moderately, and inactive SLE, respectively. Levels of IFN-?, TNF-?, and IL-12 were significantly higher in patients than in healthy controls (P < .03), as well as the IL-12/IL-10, IL-12/IL-4, IFN/IL-10, IFN/IL-4, TNF/IL-10, and TNF/IL-4 ratios (P < .01), suggesting a major participation of Th1 over Th2 cytokines. Nevertheless, a direct correlation between Th1 (IFN-? and TNF-?) and Th2 (IL-4 and IL-10) cytokines was observed in patients (r > .5, P < .01), indicating a mutual Th1-Th2 participation. TNF-? levels and the TNF/IL-10 ratio were higher in patients with inactive disease compared with patients with very active disease and controls (P < .04). IL-12 levels and IL-12/IL-4, as well as IL-12/IL-10, ratios were higher in patients with very active disease than in those with inactive SLE and controls (P < .01). IL-10 levels were associated with anti-DNA, anti-Ro, and anti-La response (P < .01).ConclusionOur results suggest that TNF-? could be a protective factor in SLE patients, whereas IL-12p70 participates in disease activity and IL-10 influences the autoimmune response (autoantibody production).application/pdfhttps://doi.org/10.1016/j.semarthrit.2003.11.002ISSN: 0049-0172EISSN: 1532-866Xhttps://repository.urosario.edu.co/handle/10336/27041engElsevier413No. 6404Seminars in Arthritis and RheumatismVol. 33Seminars in Arthritis and Rheumatism, ISSN: 0049-0172;EISSN: 1532-866X, Vol., 33 No.6 (2004); pp. 404-413https://www.sciencedirect.com/science/article/abs/pii/S0049017203002142Restringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecSeminars in Arthritis and Rheumatisminstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURSystemic lupus erythematosusCytokinesTNF-?IL-10IL12AutoantibodiesSLEDAITh1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?Citocinas Th1 / Th2 en pacientes con lupus eritematoso sistémico: ¿es protector el factor de necrosis tumoral ??articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Gómez, DianaCorrea, Paula A.Gómez, Luis MiguelCadena, JoséMolina, José F.Anaya, Juan-Manuel10336/27041oai:repository.urosario.edu.co:10336/270412021-08-13 23:21:38.785https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
dc.title.TranslatedTitle.spa.fl_str_mv Citocinas Th1 / Th2 en pacientes con lupus eritematoso sistémico: ¿es protector el factor de necrosis tumoral ??
title Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
spellingShingle Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
Systemic lupus erythematosus
Cytokines
TNF-?
IL-10IL12
Autoantibodies
SLEDAI
title_short Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
title_full Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
title_fullStr Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
title_full_unstemmed Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
title_sort Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor ? protective?
dc.subject.keyword.spa.fl_str_mv Systemic lupus erythematosus
Cytokines
TNF-?
IL-10IL12
Autoantibodies
SLEDAI
topic Systemic lupus erythematosus
Cytokines
TNF-?
IL-10IL12
Autoantibodies
SLEDAI
description Objectives: To determine the circulating levels of Th1 and Th2 cytokines in patients with systemic lupus erythematosus (SLE) and to elucidate their association with disease activity and autoimmune response.MethodsWe included 52 patients and 25 healthy controls. Serum levels of tumor necrosis factor (TNF) ?, interferon (IFN) ?, interleukin (IL)-12p70, IL-10, and IL-4, as well as anti-DNA, -Ro, -La, -RNP, and -Sm antibodies were determined by enzyme-linked immunosorbent assay. Disease activity was recorded according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and classified as very active (SLEDAI ? 13), moderately active (SLEDAI: 3–12), or inactive (SLEDAI ? 2).ResultsThe mean age of the patients was 34.2 ± 12.6 years, and the mean duration of disease was 4.9 ± 7.6 years. Twelve patients (23%), 20 patients (34.5%), and 20 patients (34.5%) had highly, moderately, and inactive SLE, respectively. Levels of IFN-?, TNF-?, and IL-12 were significantly higher in patients than in healthy controls (P < .03), as well as the IL-12/IL-10, IL-12/IL-4, IFN/IL-10, IFN/IL-4, TNF/IL-10, and TNF/IL-4 ratios (P < .01), suggesting a major participation of Th1 over Th2 cytokines. Nevertheless, a direct correlation between Th1 (IFN-? and TNF-?) and Th2 (IL-4 and IL-10) cytokines was observed in patients (r > .5, P < .01), indicating a mutual Th1-Th2 participation. TNF-? levels and the TNF/IL-10 ratio were higher in patients with inactive disease compared with patients with very active disease and controls (P < .04). IL-12 levels and IL-12/IL-4, as well as IL-12/IL-10, ratios were higher in patients with very active disease than in those with inactive SLE and controls (P < .01). IL-10 levels were associated with anti-DNA, anti-Ro, and anti-La response (P < .01).ConclusionOur results suggest that TNF-? could be a protective factor in SLE patients, whereas IL-12p70 participates in disease activity and IL-10 influences the autoimmune response (autoantibody production).
publishDate 2004
dc.date.created.spa.fl_str_mv 2004-06
dc.date.accessioned.none.fl_str_mv 2020-08-19T14:40:50Z
dc.date.available.none.fl_str_mv 2020-08-19T14:40:50Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.semarthrit.2003.11.002
dc.identifier.issn.none.fl_str_mv ISSN: 0049-0172
EISSN: 1532-866X
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/27041
url https://doi.org/10.1016/j.semarthrit.2003.11.002
https://repository.urosario.edu.co/handle/10336/27041
identifier_str_mv ISSN: 0049-0172
EISSN: 1532-866X
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 413
dc.relation.citationIssue.none.fl_str_mv No. 6
dc.relation.citationStartPage.none.fl_str_mv 404
dc.relation.citationTitle.none.fl_str_mv Seminars in Arthritis and Rheumatism
dc.relation.citationVolume.none.fl_str_mv Vol. 33
dc.relation.ispartof.spa.fl_str_mv Seminars in Arthritis and Rheumatism, ISSN: 0049-0172;EISSN: 1532-866X, Vol., 33 No.6 (2004); pp. 404-413
dc.relation.uri.spa.fl_str_mv https://www.sciencedirect.com/science/article/abs/pii/S0049017203002142
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv Restringido (Acceso a grupos específicos)
rights_invalid_str_mv Restringido (Acceso a grupos específicos)
http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.source.spa.fl_str_mv Seminars in Arthritis and Rheumatism
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167431386497024